Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;26(6):1147-1158.
doi: 10.1007/s10147-021-01887-y. Epub 2021 Mar 11.

Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors

Pierre Auloge  1 , Julien Garnon  2 , Joey Marie Robinson  2 , Marie-Aude Thenint  3 , Guillaume Koch  2 , Jean Caudrelier  2 , Julia Weiss  2 , Roberto Luigi Cazzato  2 , Jean Emmanuel Kurtz  4 , Afshin Gangi  2
Affiliations

Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors

Pierre Auloge et al. Int J Clin Oncol. 2021 Jun.

Abstract

Purpose: To assess efficacy and safety of percutaneous cryoablation (CA) for advanced and refractory extra-abdominal desmoid tumors.

Materials and methods: This retrospective study reviewed 30 consecutive patients with symptomatic desmoid tumors evolving after "wait and watch" periods, and despite medical treatment, treated by CA between 2007 and 2019. Progression free survival (PFS), objective response rate, pain reduction (decreased of visual analogic scale pain (VAS)[Formula: see text] 3 or disappearance of pain), total volume lesion (TVL) and complications were documented. Kaplan Meier method was used to outline PFS. Paired sample t test was used to compare volume of tumors before treatment and at 1 and 3 year.

Results: With a median follow-up of 18.5 months (range 6-93 months, interquartile range (IQR): 12-55), the PFS was 85.1% at 1 year and 77.3% at 3 years. Objective response was obtained for 80% of patients with a complete response for 43% patients. Pain reduction was obtained for 96.7% (95% confidence interval (95% CI): 90.3, 100) of patients. Median volume of desmoid tumor before treatment was 124.1cm3 (range 2-1727cm3, IQR: 54-338cm3). Median change of TLV after ablation was 66.6% (95% CI: 37.2, 72.3; p = 0.002) at 1 year and 76.4% (95% CI: 59.1, 89.8; p = 0.002) at 3 year. Adverse events rate was 36.6%, the most common was edema and temporary increase of pain in the days following CA. Four patients experienced a major complication (13.3%): 2 skin necrosis, 1 infection and 1 brachial plexopathy.

Conclusion: CA is an effective treatment for advanced and refractory extra-abdominal desmoid tumor, that induces durable responses.

PubMed Disclaimer

References

    1. Reitamo JJ, Häyry P, Nykyri E, Saxén E (1982) The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 77:665–673. https://doi.org/10.1093/ajcp/77.6.665 - DOI - PubMed
    1. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LMH et al (2011) A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer 129:256–261. https://doi.org/10.1002/ijc.25664 - DOI - PubMed
    1. Fallen T, Wilson M, Morlan B, Lindor NM (2006) Desmoid tumors—a characterization of patients seen at Mayo Clinic 1976–1999. Fam Cancer 5:191–194. https://doi.org/10.1007/s10689-005-5959-5 - DOI - PubMed
    1. Shields CJ, Winter DC, Kirwan WO, Redmond HP (2001) Desmoid tumours. Eur J Surg Oncol 27:701–706. https://doi.org/10.1053/ejso.2001.1169 - DOI - PubMed
    1. Bertario L, Russo A, Sala P et al (2001) Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 95:102–107. https://doi.org/10.1002/1097-0215(20010320)95:2%3c102::aid-ijc1018%3e3.0... - DOI - PubMed

LinkOut - more resources